These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18487578)

  • 21. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
    Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alchemix, p53 and topoisomerase.
    Grand RJ; Stewart GS
    Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
    [No Abstract]   [Full Text] [Related]  

  • 29. [A study on the relationship between breast cancer molecular classification and prognosis].
    Chen XS; Ma CD; Chen CM
    Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1400-3. PubMed ID: 19094512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.
    Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
    Nariţa D; Anghel A; Motoc M
    Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Estrogen and progesterone receptors and growth factors in patients with endometriosis].
    Lu M; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):633-5. PubMed ID: 9275462
    [No Abstract]   [Full Text] [Related]  

  • 38. Criteria for the evaluation of cytostatic chemotherapy.
    Dold U
    Int J Clin Pharmacol Biopharm; 1978 Feb; 16(2):68-71. PubMed ID: 631973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemotherapy of extensive and metastasized cancers].
    Israël L
    Rev Prat; 1981 Oct; 31(43):3043-4 passim. PubMed ID: 7291909
    [No Abstract]   [Full Text] [Related]  

  • 40. Personalized medicine-molecular targeted cancer therapy.
    Osamura RY; Gown AM
    J Cell Mol Med; 2009; 13(11-12):4285. PubMed ID: 19691673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.